Clinical Trials Browser

Active not recruiting × binimetinib × 1 year × Clear all

NCT05554367 2026-03-18

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT04657991 2026-03-02

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Skin Neoplasms

NCT05195632 2026-01-07

OCEANII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1/2 Active not recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04061980 2025-11-19

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Neoplasms

NCT04439344 2025-11-19

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Phase 2 Active not recruiting

53 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04526782 2025-11-18

ENCO-BRAF

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04892017 2025-10-10

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05170334 2025-10-01

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Phase 2 Active not recruiting

Uveal Melanoma, Eye Neoplasms

NCT03235245 2025-08-01

EBIN

Phase 2 Active not recruiting

Melanoma